Over 120 pediatric researchers with expertise
and experience that span the breadth of medica
disciplines comprise ACHRI’s roster of investigators
who work to fulfi ll its mission to improve children’s
health, development, and well-being through high
quality research. A few of our major research programs are described below.
Arkansas Children’s Nutrition Center
The Arkansas Children’s Nutrition Center is currently one of six national human nutrition centers funded through the United States Department of Agriculture. This center focuses specifically on diet and nutritional status of human development, using state-of-the-art procedures, equipment and facilities to determine how dietary factors and nutrition can affect brain development, learning, and attention span, as well as how early dietary intervention can prevent diseases of development and aging.
Center for Birth Defects Research and Prevention
The Center for Birth Defects Research and Prevention seeks to reduce the prevalence of birth defects in Arkansas and the nation and to reduce the economic, social, and psychological impact of birth defects at a state and national level. To accomplish this goal, the Center conducts research on the etiology and prevention of birth defects through the successful completion of high-caliber epidemiologic studies. In addition, the Center is establishing a Genomic Research Laboratory Core that will support the Center in its epidemiologic research. These resources will include high-throughput genotyping, mutation and polymorphism detection, physical mapping, sequencing and expression analysis.
Food Allergy Research Program
The Food Allergy Research Program at ACHRI has a long history of excellence in clinical and translational research for more than two decades. During the past 15 years the food allergy research program has focused on developing novel therapeutics for children and adults with food allergy through innovative, multi-center studies within the NIH/NIAID-funded Consortium of Food Allergy Research and the NIH/NIAID-funded Immune Tolerance Network, as well as through research funded through private foundation grants and industry-sponsored clinical trials. This collaborative work has resulted in significant progress toward effective immunotherapeutic approaches to the treatment of food allergy. This multi-disciplinary team of investigators has also established the Eosinophilic Gastrointestinal Disorders Clinic and Research Program with the key mission to improve care, diagnostic capabilities and treatment for children with eosinophilic esophagitis through integrated network studies and the use of novel model systems.
Asthma and Respiratory Disorders Research Program
The Asthma and Respiratory Disorders Research Program was established to address the growing problem of asthma morbidity among children. In addition to strong clinical services in asthma and allergic disease, this program provides novel research approaches to addressing pathogenesis of disease, exploring new treatment modalities through clinical trials and translational research, and improving education and healthcare delivery through community-based health outcomes research. The Lung Cell Biology Laboratory, through its collaborative NIH funding and multi-disciplinary investigative team, employs novel human model systems to investigate disease pathogenesis and explore potential targets for novel therapies. The NIH-funded rural health asthma program, RADAR (Reducing Asthma Disparities in Arkansas), utilizes state-of-the-art technology including telehealth and mobile application systems to target high-risk, under-served populations through its innovative rural healthcare delivery research.
Pediatric Pharmacology Research Unit
In 1993, ACHRI was selected to house one of the first Pediatric Pharmacology Research Units (PPRU) funded by the NIH. These centers were established in response to concerns that many medications commonly used to treat a variety of childhood illnesses have not undergone carefully controlled clinical trials to establish dosing, safety, and effectiveness in children. The PPRU Network partners with the pharmaceutical industry and other investigators nationally and locally to generate dosing, safety, and efficacy data for the use of drugs in children. ACHRI’s PPRU is a collaborative effort with numerous pediatric investigators from the following specialties: neurology, critical care medicine, pulmonary, infectious disease, nephrology, cardiology, neonatology, and general pediatrics.
Acetaminophen Toxicity Laboratory
Acetaminophen, the most commonly drug used in the treatment of pain and fever worldwide, is a major cause of acute liver failure in the US. Although generally considered safe when used in manufacturer recommended doses, acetaminophen at excessive doses can result in fatal liver injury. Current diagnosis of acetaminophen toxicity is measurement of blood levels of acetaminophen within 24 hours of overdose. Published findings from ACHRI’s Acetaminophen Toxicity Research Laboratory show that acetaminophen adducts are present for up to 12 days following large overdoses in children and adults broadening the diagnostic window. Under funds from a Small Business Technology Transfer award by NIH, our investigators are developing approaches for the measurement of adducts that could be widely used in hospitals.
Autism Research Program
At ACHRI, leaders in the field of autism spectrum disorders (ASDs) are conducting basic, clinical, and translational research to help children affected by ASDs and their families. Their research works towards a deeper understanding of the psychological, behavioral, and physiological mechanisms that cause ASD and prevent recovery. Current research projects include measuring the impact of oxidative stress, mitochondrial function, and environmental stressors on ASD. The clinical program incorporates investigator-initiated and industry-sponsored clinical trials, development of an autism clinical diagnosis and care system, and collaborations with neurologists, psychiatrists, gastroenterologists, geneticists, and others. Together, these efforts will improve the development of novel behavioral and medical therapies to accelerate and optimize recovery of children diagnosed with ASD and develop strategies for preventing ASD from developing in high-risk children.
Environmental Exposure Research Program
An environmental exposure research program aimed at diminishing the impact of pollutants on human health and the environment was initiated using funds from the Arkansas Biosciences Institute (ABI), the major research component of the Tobacco Settlement Proceeds Act of 2000. The program, established at the Arkansas Children's Hospital Research Institute, fostered key collaborations across the state and nation with researchers at institutions including Arkansas State University in Jonesboro, the University of Arkansas for Medical Sciences in Little Rock, the University of Central Arkansas in Conway, and Colorado State University in Fort Collins. The research team is examining how exposure to common environmental toxicants triggers autoimmune disease and how developmental or early life exposure to certain chemicals can increase risk of adult disease. To learn more about this work, CLICK HERE
Childhood Obesity Prevention Program
ACHRI's Childhood Obesity Prevention Research Program conducts state-of-the-art clinical, translational, and community-based research and provides leadership and coordination between various local and state partners to obtain evidence that can be used to develop strategies leading to the prevention of childhood obesity. Specifically, the program 1) conducts research to further our understanding of the causes of childhood obesity, 2) partners with the state and communities to develop strategies for the prevention of childhood obesity in Arkansas, 3) works to develop an evidence base upon which state and local policymakers can create new approaches to reduce overweight and obesity in Arkansas children, and 4) serve as an educational resource center for childhood obesity prevention programming.
Pediatric Comparative Effectiveness Research Program
The goal of the pediatric comparative effectiveness research (PCER) program at ACHRI is to grow and develop comparative effectiveness research among the University of Arkansas for Medical Sciences (UAMS)/Arkansas Children's Hospital (ACH) pediatric faculty. This program aims to provide consultation, mentoring, and/or partnership to clinicians to pursue comparative effectiveness research questions for publication and funding, provide connections to a network of experts and cores in various aspects of comparative effectiveness research; support training in comparative effectiveness research; etc. To learn more about the PCER program, visit http://www.achri.archildrens.org/PCER.html.
Chlamydia Research Group
The Chlamydia Research Group continues the study of chlamydial infections begun in 1974 by the late Dr. Almen Barron. Since then, its researchers have had continual NIH research funding and publications for 40 years as well as international recognition for their expertise on the immunology and pathogenesis of chlamydial genital infections. Among the groups studies studies is the exploration of the concept that Chlamydia can persist in the gastrointestinal tract indefinitely, protected from the immune response, and serve as a source of bacteria for reinfection of the genital tract, particularly in women. In addition to its laboratory activities, the work of the Chlamydia Research Group also includes models of infection for researchers to use. These models include not just animal models, but also biomedical mathematical models.